Literature DB >> 11923547

Can mandibular advancement devices be a satisfactory substitute for short term use in patients on nasal continuous positive airway pressure?

D M Smith1, J R Stradling.   

Abstract

BACKGROUND: Mandibular advancement devices (MADs) can successfully control both snoring and obstructive sleep apnoea (OSA). Many patients on nasal continuous positive airway pressure (NCPAP) for OSA would like a more portable alternative, even if only temporarily. This study assesses what proportion of patients with OSA already on NCPAP can successfully use a MAD for short periods (up to 1 month) as a temporary alternative to NCPAP.
METHODS: Fifty patients with OSA, already on NCPAP for at least 3 months, were recruited by invitation. They were provided with a simple fixed MAD estimated to provide 75% of maximum mandibular protrusion. Sleep studies using a portable home recorder were performed on and after three nights without NCPAP to provide control data. Following acclimatisation to the MAD, sleep studies were also planned after 3, 7, and 28 days while using the MAD. If their overnight >4% SaO(2) dips per hour deteriorated to >20 or the Epworth sleepiness score (ESS) rose to >9 (or increased by >4 over baseline) on nights 3 or 7, they were then deemed to have failed the trial and were withdrawn.
RESULTS: Of the 50 patients entered, one had inadequate teeth for a MAD and 31 gave up trying to use the device during the acclimatisation period because of side effects. Of the 18 prepared to use the device, two patients failed at night 3, five at night 7, and two at night 28. Thus, nine patients remained controlled by our criteria at night 28. On average, sleep study indices while using the MAD were poor compared with the night on NCPAP.
CONCLUSIONS: Simple MADs are poorly tolerated by patients with OSA already on NCPAP. OSA was adequately controlled by our criteria in 32% of those recruited for the equivalent of a weekend, in 22% for 1 week, and in 18% for up to 1 month. Better tolerated devices would be likely to improve on these figures.

Entities:  

Mesh:

Year:  2002        PMID: 11923547      PMCID: PMC1746287          DOI: 10.1136/thorax.57.4.305

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  22 in total

1.  Relation between systemic hypertension and sleep hypoxaemia or snoring: analysis in 748 men drawn from general practice.

Authors:  J R Stradling; J H Crosby
Journal:  BMJ       Date:  1990-01-13

2.  Pulse wave velocity and blood pressure change: calibration and applications.

Authors:  A Steptoe; H Smulyan; B Gribbin
Journal:  Psychophysiology       Date:  1976-09       Impact factor: 4.016

3.  Which aspects of breathing during sleep influence the overnight fall of blood pressure in a community population?

Authors:  J R Stradling; C Barbour; J Glennon; B A Langford; J H Crosby
Journal:  Thorax       Date:  2000-05       Impact factor: 9.139

4.  Long-term use of mandibular advancement splints for snoring and obstructive sleep apnoea: a questionnaire survey.

Authors:  A D McGown; H K Makker; J M Battagel; P R L'Estrange; H R Grant; S G Spiro
Journal:  Eur Respir J       Date:  2001-03       Impact factor: 16.671

5.  Comparison of esophageal pressure with pulse transit time as a measure of respiratory effort for scoring obstructive nonapneic respiratory events.

Authors:  J Argod; J L Pépin; R P Smith; P Lévy
Journal:  Am J Respir Crit Care Med       Date:  2000-07       Impact factor: 21.405

6.  Arterial blood pressure responses to graded transient arousal from sleep in normal humans.

Authors:  R J Davies; P J Belt; S J Roberts; N J Ali; J R Stradling
Journal:  J Appl Physiol (1985)       Date:  1993-03

7.  Aortic-radial pulse transit time and ECG Q-wave to radial pulse wave interval as indices of beat-by-beat blood pressure change.

Authors:  M H Pollak; P A Obrist
Journal:  Psychophysiology       Date:  1983-01       Impact factor: 4.016

8.  Mandibular advancement oral appliance therapy for obstructive sleep apnoea: effect on awake calibre of the velopharynx.

Authors:  C F Ryan; L L Love; D Peat; J A Fleetham; A A Lowe
Journal:  Thorax       Date:  1999-11       Impact factor: 9.139

9.  Prevalence of sleepiness and its relation to autonomic evidence of arousals and increased inspiratory effort in a community based population of men and women.

Authors:  J R Stradling; C Barbour; J Glennon; B A Langford; J H Crosby
Journal:  J Sleep Res       Date:  2000-12       Impact factor: 3.981

10.  Daytime sleepiness, snoring, and obstructive sleep apnea. The Epworth Sleepiness Scale.

Authors:  M W Johns
Journal:  Chest       Date:  1993-01       Impact factor: 9.410

View more
  5 in total

1.  Obstructive sleep apnea: can the downward spiral be reversed-a summary of John Stradling's ATS keynote speech.

Authors:  Matthew B McCarra; Robert L Owens
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

2.  Mandibular advancement splint as short-term alternative treatment in patients with obstructive sleep apnea already effectively treated with continuous positive airway pressure.

Authors:  Fernanda R Almeida; Alan Mulgrew; Najib Ayas; Hiroko Tsuda; Alan A Lowe; Nurit Fox; Sandra Harrison; John A Fleetham
Journal:  J Clin Sleep Med       Date:  2013-04-15       Impact factor: 4.062

3.  Mandibular Advancement Device as a Comparable Treatment to Nasal Continuous Positive Airway Pressure for Positional Obstructive Sleep Apnea.

Authors:  Yoshikazu Takaesu; Satoru Tsuiki; Mina Kobayashi; Yoko Komada; Hideaki Nakayama; Yuichi Inoue
Journal:  J Clin Sleep Med       Date:  2016-08-15       Impact factor: 4.062

4.  Objective measurement of compliance during oral appliance therapy for sleep-disordered breathing.

Authors:  Olivier M Vanderveken; Marijke Dieltjens; Kristien Wouters; Wilfried A De Backer; Paul H Van de Heyning; Marc J Braem
Journal:  Thorax       Date:  2012-09-19       Impact factor: 9.139

Review 5.  Review of oral appliances for treatment of sleep-disordered breathing.

Authors:  Victor Hoffstein
Journal:  Sleep Breath       Date:  2007-03       Impact factor: 2.816

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.